Herpes simplex virus gingivostomatitis

Summary

Herpes simplex virus gingivostomatitis (MONDO:0005792) is a disease and 4 clinical trials. Top therapeutic interventions include valacyclovir. A subtype of herpes simplex infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	herpes simplex virus gingivostomatitis
Mondo ID	MONDO:0005792
EFO	EFO:0007307
MeSH	D013283
SNOMED CT	57920007
Is cancer (heuristic)	no

Also known as: Gingivostomatitides, herpetic · Gingivostomatitis, herpetic · Herpes simplex, oral · herpetic Gingivostomatitides · herpetic Gingivostomatitis · herpetic Stomatitides · herpetic stomatitis · oral Herpes simplex · simplex, oral Herpes · Simplexvirus caused stomatitis · Simplexvirus stomatitis · Stomatitides, herpetic

Disease family

This is a subtype of herpes simplex infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Herpesviridae infectious disease › herpes simplex infectious disease › herpes simplex virus gingivostomatitis

Related subtypes (9): herpetic whitlow, herpes simplex dermatitis, genital herpes, herpes simplex encephalitis, herpes simplex virus keratitis, congenital herpes simplex virus infection, herpes labialis, herpes simplex type 1 infectious disease, herpes simplex type 2 infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Valacyclovir.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01308424	PHASE1/PHASE2	COMPLETED	Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection
NCT01902303	PHASE2	COMPLETED	Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores
NCT02738229	PHASE2	COMPLETED	Should We Use Oral Valacyclovir in Acute Herpetic Gingivostomatitis in Children?
NCT06778655	Not specified	COMPLETED	Propolis in Primary Herpetic Gingivostomatitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
VALACYCLOVIR	4	1